Loading...
•
Sep 30, 2021
Rhythm Pharmaceuticals Q3 2021 Earnings Report
Reported financial results for the third quarter ended September 30, 2021.
Key Takeaways
Rhythm Pharmaceuticals reported their Q3 2021 financial results, highlighting the submission of regulatory filings in the U.S. and EU for IMCIVREE for the treatment of Bardet-Biedl and Alström syndromes and the ongoing launch preparations.
Submitted U.S. and EU regulatory filings for IMCIVREE® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes.
Delivered a total of 22 presentations at three major medical conferences.
IMCIVREE third quarter net sales reached $1M.
Existing cash, cash equivalents and short-term investments as of September 30, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements into at least the second half of 2023.
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Forward Guidance
Rhythm expects that its existing cash, cash equivalents and short-term investments as of September 30, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements into at least the second half of 2023.